Beta Bionics Inc(BBNX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 5 at 4:52 PM ET (Korea 11/6 06:52)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.85 | Insider Own | 13.93% | Shs Outstand | 54.4M | Perf Week | -12% |
| Market Cap | 0.84B | Forward P/E | - | EPS next Y | -3.99% | Insider Trans | -2.36% | Shs Float | 46.8M | Perf Month | -14.44% |
| Enterprise Value | 0.61B | PEG | - | EPS next Q | -0.5 | Inst Own | 96.94% | Short Float | 14.78% | Perf Quarter | -2.7% |
| Income | -0.08B | P/S | 6.61 | EPS this Y | -12.96% | Inst Trans | 15.7% | Short Ratio | 5.72 | Perf Half Y | 47.33% |
| Sales | 0.13B | P/B | 2.1 | EPS next 5Y | 4.23% | ROA | -21.48% | Short Interest | 6.92M | Perf YTD | -49.23% |
| Book/sh | 7.38 | P/C | 3.5 | EPS past 3/5Y | -6.13% - | ROE | -23.88% | 52W High | -52.71% ($32.71) | Perf Year | -41.64% |
| Cash/sh | 4.42 | P/FCF | - | Sales past 3/5Y | 724.29% - | ROIC | -20.47% | 52W Low | 75.8% ($8.80) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -3% | Gross Margin | 58.63% | Volatility(W/M) | 9.16% 7.44% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 4.77 | Sales Y/Y TTM | 43.69% | Oper. Margin | -72.75% | ATR (14) | 1.57 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.22 | EPS Q/Q | -60.69% | Profit Margin | -65.31% | RSI (14) | 40.14 | Recom | 1.6 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.92 | Sales Q/Q | 30.28% | SMA20 | -12.27% ($17.63) | Beta | 3.43 | Target Price | $25.1 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/10/27 | SMA50 | -17.82% ($18.82) | Rel Volume | 1.07 | Prev Close | $16.95 |
| Employees | 423 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 0.63% 2.26% | SMA200 | 4.68% ($14.78) | Avg Volume(3M) | 1.21M | Price | $15.47 |
| IPO | 2025/1/30 | Option/Short | Yes/Yes | Trades | 11972 | Volume | 1,295,106 | Change | -8.73% |
🩸 Beta Bionics (BBNX) is a US medical device company that develops and commercializes the iLet Bionic Pancreas, an automated insulin delivery system for insulin-dependent diabetes patients. With a simplified design that reduces complex manual calculations and enhances ease of use as its key differentiator, the company is rapidly expanding its footprint in the diabetes management device market.
Over the past 1 year, roughly in the middle
53% below its 1-year high.
Traded about as much as usual. That is 107% of its average volume.
BBNX has a sound balance sheet but weak earning power
Of every $100 in sales, $72.75 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -13.0% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $661. Peers typically go for $338.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 5 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 96.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #47 of 140 in the industry
Based on market cap of $841M.
BVS#44 Bioventus Inc $900M PER 13.2 
QDEL#45 QuidelOrtho Corp $881M PER - 
KIDS#46 OrthoPediatrics corp $841M PER - BBNX#47 Beta Bionics Inc $841M PER - 
VREX#48 Varex Imaging Corp $783M PER 35.3 
FAQ
What kind of company is BBNX?
BBNX belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of BBNX?
The market cap of BBNX is approximately $841M, ranking 2,686 within its sector.
What is the 52-week high and low for BBNX?
BBNX has recorded a 52-week high of $32.71 and a low of $8.80.
